{"id":61362,"date":"2025-06-03T10:03:10","date_gmt":"2025-06-03T08:03:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/"},"modified":"2025-06-03T10:03:10","modified_gmt":"2025-06-03T08:03:10","slug":"leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/","title":{"rendered":"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nEuropean Investment Bank and Leyden Labs sign \u20ac20 million financing to advance Leyden Labs\u2019 pandemic preparedness activities, guaranteed by European Commission\u2019s InvestEU initiative through its Health Emergency Preparedness and Response (HERA).<\/li>\n<li>\nFunding is part of \u201cHERA Invest,\u201d a \u20ac110 million top-up to the European Union\u2019s InvestEU initiative, meant to address pandemic readiness, biodefense and antimicrobial resistance.<\/li>\n<li>\nLeyden Labs will use the funding to advance development of its novel non-vaccine approach, with nasal sprays containing broadly-protective antibodies to defend against seasonal and pandemic viral infections.<\/li>\n<\/ul>\n<p>LUXEMBOURG &amp; LEIDEN, the Netherlands&#8211;(BUSINESS WIRE)&#8211;The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a \u20ac20 million financing deal to advance development of the Company\u2019s broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs\u2019 lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protection and meaningfully reduce the burden of influenza infection, including in infection from Avian Flu (H5).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/4\/Untitled.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/22\/Untitled.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/4\/Untitled.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/21\/Untitled.jpg\"><\/a><\/p>\n<p>\nThe venture debt financing agreement is supported under the European Commission\u2019s InvestEU programme and specifically falls under \u201cHERA Invest.\u201d This \u20ac110 million initiative from the European Health Union is meant to address biodefence, pandemic readiness and antimicrobial resistance in Europe, as a top-up to the European Union\u2019s InvestEU initiative, funded by the EU4Health programme.<\/p>\n<p>\n<i>\u201cThe COVID-19 pandemic taught us multiple lessons, including that we should strengthen the EU&#8217;s preparedness and autonomy in key areas like bio sciences,\u201d <\/i>stated EIB Vice President <b>Robert de Groot<\/b><i>. \u201cWith the support of the European Commission, the EIB backs highly innovative EU companies like Leyden Labs with venture debt, enabling them to grow and thrive in Europe. Technological innovations from companies like Leyden Labs are key for European competitiveness and the well-being of our society.\u201d<\/i><\/p>\n<p>\n<b>Hadja<\/b> <b>Lahbib<\/b>, Commissioner for Equality, Preparedness and Crisis Management, added:<i> \u201cRespiratory viruses are common and affect us all, especially the most medically vulnerable. Today\u2019s agreement reaffirms our commitment to invest in innovation to strengthen preparedness and protection against respiratory viruses. HERA Invest is a prime example of Europe at the forefront of medical advancements in response to serious threats to health.\u201d<\/i><\/p>\n<p>\n<i>\u201cWe are thrilled with this endorsement of our approach and support from HERA and the European Investment Bank. This will accelerate our efforts to provide broad, universal protection against current and future viral outbreaks. We are grateful that HERA and the EIB understand the urgency and significance of investing in initiatives to ensure Europe is prepared for pandemic viruses. This concern is greater than ever given the increasing threat of an avian influenza outbreak,\u201d<\/i> said <b>Koenraad Wiedhaup<\/b>, co-founder and CEO of Leyden Labs.<\/p>\n<p>\nLeyden Labs\u2019 product candidates are nasal sprays that administer broadly protective antibodies directly to the respiratory mucosa. Leyden Lab\u2019s solutions are designed to work at the earliest moment, before the virus even reaches systemic circulation. Systemically administered vaccines primarily generate systemic protection against viruses, however, this may be a limitation that contributes to suboptimal efficacy. Airborne viruses, including influenza, do not directly enter systemic circulation, but rather, they enter the body through the nose and mouth. The Company\u2019s antibodies aim to protect against full viral families, so they keep working even when a virus mutates and evolves. This intranasal strategy also has the potential to benefit people with weakened immune systems because it does not rely on the person to be able to mount an immune response in order to be protective.<\/p>\n<p>\nThe Company\u2019s novel approach has the potential to transform the way the healthcare ecosystem thinks about viral prophylaxis, while also providing an innovative solution for use both in times of seasonal outbreaks as well as pandemic emergencies.<\/p>\n<p>\nHERA\u2019s responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats. The \u20ac20 million proceeds of this financing will support further development of Leyden Labs\u2019 novel, non-vaccine approach to fighting respiratory viruses to contribute to European pandemic preparedness efforts.<\/p>\n<p>\n<b>Background Information:<\/b><\/p>\n<p>\n<b>Health Emergency Preparedness and Response (HERA). <\/b>The European Commission&#8217;s Health Emergency Preparedness and Response Authority (HERA) supports projects that strengthen preparedness and response capacities in the field of health. HERA was established as a direct consequence of the lessons learned from the initial management of the COVID-19 pandemic, to ensure a solid Union response to serious-cross border health threats and secure ready availability and accessibility of medical countermeasures<b>.<\/b> HERA\u2019s responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats, and its mandate covers both the strengthening of preparedness in advance of future emergencies and the implementation of a swift and efficient response once crisis hits.<\/p>\n<p>\n<b>HERA Invest<\/b> is a \u20ac110 million top-up to the InvestEU programme, funded by the EU4Health programme. It is implemented by the EIB and supports projects that focus on pathogens with pandemic potential, chemical, biological, radiological, nuclear threats, and antimicrobial resistance. Together with HERA, the EIB assesses whether an operation meets HERA Invest\u2019s criteria.<\/p>\n<p>\nThe <b>InvestEU programme<\/b> provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilise private investment for EU policy priorities, such as the European Green Deal and the digital transition. InvestEU brings together under one roof the multitude of EU financial instruments previously available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is deployed through implementing partners who will invest in projects using the EU budget guarantee of \u20ac26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least \u20ac372 billion in additional investment.<\/p>\n<p>\nThe <b>European Investment Bank (EIB)<\/b> is the long-term lending institution of the European Union, owned by its Member States. The Netherlands owns a 5,2% share of the EIB. It makes long-term finance available for sound investment in order to contribute towards EU policy goals and national priorities. More than 90% of its activity is in <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.eib.org%2Fprojects%2Fregions%2Feuropean-union%2Findex.htm&amp;esheet=54263768&amp;newsitemid=20250603017541&amp;lan=en-US&amp;anchor=Europe&amp;index=1&amp;md5=b9d5178c7ddeed19ae8239f418534e8d\" rel=\"nofollow\" shape=\"rect\">Europe<\/a>. Over the last ten years, the EIB has made available more than \u20ac27 billion in financing for Dutch projects in various sectors, including research &amp; development, sustainable mobility, drinking water, healthcare and SMEs. In 2024 the EIB Group, which also includes the EIB\u2019s subsidiary, the European Investment Fund (EIF), made available more than \u20ac3 billion for Dutch projects.<\/p>\n<p>\n<b>Leyden Laboratories B.V.<\/b> (Leyden Labs), founded in 2020, is a clinical-stage biotechnology company based in the Netherlands. Leyden Labs is working to free people from the threat of respiratory viruses, by leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays. Leyden Labs is supported by a strong syndicate of investors and ambassadors; VC investors include GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (a life sciences venture investor established by Temasek), Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital \/ Brook Byers and Bluebird Ventures. To learn more, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.leydenlabs.com&amp;esheet=54263768&amp;newsitemid=20250603017541&amp;lan=en-US&amp;anchor=www.leydenlabs.com&amp;index=2&amp;md5=acb7e4394a6cc9181d32bc837354b842\" rel=\"nofollow\" shape=\"rect\">www.leydenlabs.com<\/a>.<\/p>\n<p>\n<b>CR9114<\/b>, Leyden Labs\u2019 lead product candidate for the PanFlu program, is a human monoclonal antibody that protects against influenza in preclinical models. Leyden Labs holds an exclusive license from Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize CR9114.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media and Investor Contacts: <\/b><\/p>\n<p>\n<b>E<\/b><b>IB Media Contact<\/b>: Tim Smit | +352 691 286423 | <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x74;&#x2e;&#115;m&#x69;&#116;&#64;&#x65;&#x69;&#98;&#46;&#x6f;&#x72;&#103;\" rel=\"nofollow\" shape=\"rect\">t&#46;&#115;&#109;&#x69;&#x74;&#x40;&#x65;ib&#46;&#111;&#x72;&#x67;<\/a><br \/><b>Leyden Labs Media Contact<\/b>: Megan Prock McGrath | CTD Comms | +1 978-800-7468 | <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x6d;&#101;d&#x69;&#x61;&#64;l&#x65;&#121;d&#x65;&#x6e;&#108;a&#x62;&#x73;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x6d;&#101;&#x64;&#105;a&#x40;&#108;e&#x79;&#100;&#x65;&#x6e;l&#x61;&#98;s&#x2e;&#99;&#x6f;&#x6d;<\/a><br \/><b>Leyden Labs Investor Contact<\/b>: Elizabeth Goodwin | +1 781-460-1784 | <a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#105;&#x6e;&#118;&#x65;&#115;&#x74;o&#x72;s&#64;&#x6c;&#101;&#x79;d&#x65;n&#x6c;&#x61;&#98;&#x73;&#46;&#x63;o&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x69;&#x6e;&#x76;&#x65;&#x73;&#x74;&#x6f;&#x72;&#x73;&#x40;&#x6c;&#101;&#121;&#100;&#101;&#110;&#108;&#97;bs&#46;com<\/a><br \/><b>European Commission<\/b>: Darragh Cassidy | +32 229 83978 | <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x44;&#x61;&#114;r&#x61;&#103;h&#x2e;&#x43;&#65;S&#x53;&#x49;&#68;Y&#x40;&#101;&#99;&#x2e;&#x65;&#117;r&#x6f;&#x70;&#97;&#46;&#x65;&#117;\" rel=\"nofollow\" shape=\"rect\">&#x44;&#x61;&#x72;&#x72;&#x61;&#x67;&#x68;&#x2e;&#x43;&#x41;&#x53;&#x53;&#x49;&#x44;&#89;&#64;&#101;&#99;&#46;&#101;&#117;&#114;&#111;&#112;&#97;&#46;eu<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>European Investment Bank and Leyden Labs sign \u20ac20 million financing to advance Leyden Labs\u2019 pandemic preparedness activities, guaranteed by European Commission\u2019s InvestEU initiative through its Health Emergency Preparedness and Response (HERA). Funding is part of \u201cHERA Invest,\u201d a \u20ac110 million top-up to the European Union\u2019s InvestEU initiative, meant to address pandemic readiness, biodefense and antimicrobial &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61362","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"European Investment Bank and Leyden Labs sign \u20ac20 million financing to advance Leyden Labs\u2019 pandemic preparedness activities, guaranteed by European Commission\u2019s InvestEU initiative through its Health Emergency Preparedness and Response (HERA). Funding is part of \u201cHERA Invest,\u201d a \u20ac110 million top-up to the European Union\u2019s InvestEU initiative, meant to address pandemic readiness, biodefense and antimicrobial ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T08:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/22\/Untitled.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities\",\"datePublished\":\"2025-06-03T08:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/\"},\"wordCount\":1318,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603017541\\\/en\\\/2486201\\\/22\\\/Untitled.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/\",\"name\":\"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603017541\\\/en\\\/2486201\\\/22\\\/Untitled.jpg\",\"datePublished\":\"2025-06-03T08:03:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603017541\\\/en\\\/2486201\\\/22\\\/Untitled.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603017541\\\/en\\\/2486201\\\/22\\\/Untitled.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/","og_locale":"en_US","og_type":"article","og_title":"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities - Pharma Trend","og_description":"European Investment Bank and Leyden Labs sign \u20ac20 million financing to advance Leyden Labs\u2019 pandemic preparedness activities, guaranteed by European Commission\u2019s InvestEU initiative through its Health Emergency Preparedness and Response (HERA). Funding is part of \u201cHERA Invest,\u201d a \u20ac110 million top-up to the European Union\u2019s InvestEU initiative, meant to address pandemic readiness, biodefense and antimicrobial ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-03T08:03:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/22\/Untitled.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities","datePublished":"2025-06-03T08:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/"},"wordCount":1318,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/22\/Untitled.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/","url":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/","name":"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/22\/Untitled.jpg","datePublished":"2025-06-03T08:03:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/22\/Untitled.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250603017541\/en\/2486201\/22\/Untitled.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera-to-advance-pandemic-preparedness-activities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Leyden Labs Lands \u20ac20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61362"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61362\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}